Inhibikase Therapeutics (IKT) Insider Aurentz Buys 155,000 Shares

Vincent Aurentz, an insider at Inhibikase Therapeutics, Inc. (NasdaqCM: IKT), purchased 155,000 shares of the company on June 26, 2026. This transaction was not part of a planned trading program, and the shares were acquired at a price not specified in the filing.

Insider Buying and Selling at Inhibikase Therapeutics, Inc.

On June 26, 2026, Vincent Aurentz was among several insiders, including David Canner and Roberto Bellini, who each purchased 155,000 shares of Inhibikase Therapeutics. These transactions were not conducted under Rule 10b5-1 trading plans.

Inhibikase Therapeutics, Inc. Stock Down 11.7%

Shares of NasdaqCM:IKT traded near $2.03 on Wednesday. Inhibikase Therapeutics has a market cap of approximately $268 million and a forward P/E ratio that is not meaningful due to its lack of profitability. The stock's beta is 0.974, indicating moderate volatility compared to the market. Inhibikase's 52-week trading range is between $1.33 and $2.26. The 50-day moving average is $1.80, while the 200-day moving average stands at $1.71. The company maintains a strong liquidity position with a current ratio of 30.14 and a quick ratio of 29.83.

Analysts Set New Price Targets

On June 10, 2026, Oppenheimer initiated coverage on Inhibikase Therapeutics with a 'buy' rating and a $5 price target. Ladenburg Thalmann and B of A Securities also initiated 'buy' ratings earlier in the year, with targets of $4 and $6, respectively. The consensus among analysts is a 'buy' recommendation, with a mean target price of $5.88 based on eight opinions.

About Inhibikase Therapeutics

Inhibikase Therapeutics, Inc. is a biotechnology company based in Wilmington, Delaware. It focuses on developing treatments for cardiopulmonary diseases, particularly pulmonary arterial hypertension (PAH). The company's lead product, IKT-001, is an oral prodrug of imatinib mesylate aimed at improving treatment for PAH. Inhibikase is conducting a global Phase 3 trial to evaluate its efficacy. Founded in 2008, the company is led by CEO Mark T. Iwicki and employs 35 people.

Bottom Line

Vincent Aurentz's recent purchase of Inhibikase Therapeutics shares adds to the insider buying activity at the company. The stock, trading at $2.03, is closely watched by analysts who have initiated 'buy' ratings with varied price targets. Investors often track insider transactions as potential indicators of confidence in the company's future prospects.